TY - JOUR
T1 - Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program
T2 - A case in Lutetium-177 prostate-specific membrane antigen (PSMA) therapy
AU - Zoberi, Jacqueline E.
AU - Garcia-Ramirez, Jose
AU - Luechtefeld, David
AU - Maughan, Nichole M.
AU - Amurao, Maxwell
AU - Oyama, Reiko
AU - Baumann, Brian
AU - Gay, Hiram A.
AU - Michalski, Jeff M.
N1 - Funding Information:
We express our gratitude to Areti Marko who is the Brachytherapy Supervisor, to Lindsey Brunt who is the Associate Director of Clinical Research, and to their respective teams for their support in implementing Lu-177 PSMA-617 therapies in our center. We would also like to thank our patients for allowing us to care for them.
Publisher Copyright:
© 2023 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine.
PY - 2023/4
Y1 - 2023/4
N2 - Prostate-specific membrane antigen (PSMA) is a cell surface protein highly expressed in nearly all prostate cancers, with restricted expression in some normal tissues. The differential expression of PSMA from tumor to non-tumor tissue has resulted in the investigation of numerous targeting strategies for therapy of patients with metastatic prostate cancer. In March of 2022, the FDA granted approval for the use of lutetium-177 PSMA-617 (Lu-177-PSMA-617) for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Therefore, the use of Lu-177-PSMA-617 is expected to increase and become more widespread. Herein, we describe logistical, technical, and radiation safety considerations for implementing a radiopharmaceutical therapy program, with particular focus on the development of operating procedures for therapeutic administrations. Major steps for a center in the U.S. to implement a new radiopharmaceutical therapy (RPT) program are listed below, and then demonstrated in greater detail via examples for Lu-177-PSMA-617 therapy.
AB - Prostate-specific membrane antigen (PSMA) is a cell surface protein highly expressed in nearly all prostate cancers, with restricted expression in some normal tissues. The differential expression of PSMA from tumor to non-tumor tissue has resulted in the investigation of numerous targeting strategies for therapy of patients with metastatic prostate cancer. In March of 2022, the FDA granted approval for the use of lutetium-177 PSMA-617 (Lu-177-PSMA-617) for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Therefore, the use of Lu-177-PSMA-617 is expected to increase and become more widespread. Herein, we describe logistical, technical, and radiation safety considerations for implementing a radiopharmaceutical therapy program, with particular focus on the development of operating procedures for therapeutic administrations. Major steps for a center in the U.S. to implement a new radiopharmaceutical therapy (RPT) program are listed below, and then demonstrated in greater detail via examples for Lu-177-PSMA-617 therapy.
KW - QA/QC
KW - commissioning
KW - radiopharmaceutical therapy
KW - safety
UR - http://www.scopus.com/inward/record.url?scp=85146335016&partnerID=8YFLogxK
U2 - 10.1002/acm2.13899
DO - 10.1002/acm2.13899
M3 - Article
C2 - 36637862
AN - SCOPUS:85146335016
SN - 1526-9914
VL - 24
JO - Journal of applied clinical medical physics
JF - Journal of applied clinical medical physics
IS - 4
M1 - e13899
ER -